Pfizer/Pharmacia Merger: Tidbits From The SEC Filings
Executive Summary
COX-2 co-marketing amendment: Pfizer would gain majority control over Pfizer/Pharmacia COX-2 co-marketing executive committee should Pharmacia terminate the merger agreement under certain conditions, Pfizer's Aug. 14 S-4 merger filing with the Securities & Exchange Commission states. Pfizer would name three members to the five-person committee should Pharmacia end the deal; Pfizer is currently represented by two members. The company would also be able to appoint a chairperson to "any or all" of the six subcommittees of the executive committee under the amended agreement. The merger breakup fee is $1.6 bil...
You may also be interested in...
Pfizer $11 Bil. Premium For Pharmacia Calibrated To Merger Savings
Pfizer's $11 bil. premium above Pharmacia's recent stock market valuation is a figure calculated from the estimated operating savings in the companies' proposed stock-for-stock transaction
Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market
Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients
Pfizer Neurontin Neuropathic Pain NDA Planned; Relpax Awaits New Study
Pfizer is preparing an NDA supplement for Neurontin that could allow open marketing of gabapentin for neuropathic pain indications.